Diltiazem Protocol for Rate Control in Atrial Fibrillation

Initial Intravenous Bolus Dosing

Administer an initial IV bolus of diltiazem 0.25 mg/kg (≈15–20 mg) over 2 minutes in hemodynamically stable adults with atrial fibrillation and rapid ventricular response. 1, 2, 3
If heart rate remains inadequately controlled after 15 minutes, give a second IV bolus of diltiazem 0.35 mg/kg (≈20–25 mg) over 2 minutes. 1, 2
Maximal heart‑rate reduction occurs within 2–7 minutes after bolus administration, with a median onset of 4.3 minutes. 3

Start a continuous diltiazem infusion at 5 mg/hour after bolus dosing. 1, 2, 3
Titrate the infusion upward to 10 mg/hour if rate control is insufficient, and further to 15 mg/hour as needed, adjusting every 1–2 hours based on heart‑rate response. 1, 2, 3
Continue the infusion until target heart rate (<100 bpm or >20 % reduction from baseline) is achieved and the patient can be transitioned to oral therapy. 3

After achieving adequate IV rate control, switch to oral immediate‑release diltiazem, typically 30 mg, and then maintain with 30–60 mg every 6–8 hours, titrating according to response. 3

Do not use diltiazem in patients with heart failure with reduced ejection fraction or decompensated heart failure, due to risk of hemodynamic collapse. 1, 4, 3
Avoid diltiazem in pre‑excitation syndromes such as Wolff‑Parkinson‑White, because it may accelerate ventricular response and precipitate ventricular fibrillation. 1, 2, 3
Diltiazem is contraindicated in wide‑complex tachycardias or rhythms consistent with ventricular tachycardia. 1, 2

Continuously monitor heart rate during bolus and infusion; watch for inadequate response or excessive bradycardia (<50 bpm or symptomatic). 1, 3
Elderly patients and those with paroxysmal atrial fibrillation have an increased risk of bradycardia. 3
If bradycardia occurs, consider dose reduction or discontinuation of diltiazem. 1
Monitor for signs of worsening heart failure, as diltiazem’s negative inotropic effect can precipitate decompensation. 1, 2

Verify hemodynamic stability (systolic BP ≥ 90 mmHg) before initiating therapy. 4
Exclude absolute contraindications (heart failure, pre‑excitation, wide‑complex tachycardia). 1
Administer the first bolus (0.25 mg/kg); reassess at 15 minutes and give a second bolus (0.35 mg/kg) if needed. 1
Initiate a continuous infusion at 5 mg/hour if further rate control is required. 1
Titrate infusion every 1–2 hours (5 → 10 → 15 mg/hour) based on heart‑rate targets. 1
Transition to oral diltiazem once stable rate control is achieved. 1, 2, 3

The American College of Cardiology and American Heart Association recommend beta-blockers or non-dihydropyridine calcium channel blockers, such as diltiazem, as first-line agents for acute rate control in hemodynamically stable patients with atrial fibrillation and rapid ventricular response 5, 6, 7, 8
The European Society of Cardiology guidelines suggest beta-blockers or diltiazem/verapamil as first-line for patients with left ventricular ejection fraction (LVEF) ≥40% 9
The American College of Cardiology and American Heart Association give a Class I, Level of Evidence B recommendation for IV diltiazem or verapamil in the acute setting 6, 7, 8

Diltiazem is contraindicated in patients with heart failure with reduced ejection fraction (HFrEF) or decompensated heart failure, as it may exacerbate hemodynamic compromise 9, 6, 7, 8, 10
Diltiazem is also contraindicated in patients with pre-excitation syndromes, such as Wolff-Parkinson-White (WPW) syndrome, as it may paradoxically accelerate ventricular response 6, 7, 8
Amiodarone should be reserved for patients with hemodynamic instability who cannot undergo immediate cardioversion, or for those with severely reduced LVEF where beta-blockers have failed 9

The initial bolus dose of diltiazem is 0.25 mg/kg IV over 2 minutes, with a second bolus of 0.35 mg/kg if inadequate response after 15 minutes 8
The maintenance infusion dose of diltiazem is 5-15 mg/hour IV 8
Metoprolol may be used as an alternative, with a dose of 2.5-5 mg IV bolus over 2 minutes, repeated every 5 minutes up to 15 mg total 8

Hypotension is a common side effect of diltiazem, occurring in 18-42% of patients, and may require intervention in 3.2% of patients 8
Continuous ECG monitoring and frequent blood pressure measurements are mandatory during IV diltiazem administration 8
Bradycardia is a potential side effect of diltiazem, particularly in elderly patients or those with paroxysmal atrial fibrillation 8

The recommended resting heart‑rate target for rate control is < 100 bpm for lenient control or < 80 bpm for strict control, as advised by the European Society of Cardiology (ESC) guidelines. 14

Diltiazem is contraindicated in patients with heart failure with reduced ejection fraction (HFrEF) or decompensated heart failure because its negative inotropic effect can precipitate hemodynamic collapse. 14
Diltiazem should not be used in Wolff‑Parkinson‑White syndrome or other pre‑excitation syndromes, as it may accelerate ventricular response via the accessory pathway and provoke ventricular fibrillation. (American College of Cardiology, ACC) 15

Beta‑blockers (metoprolol or esmolol) are preferred over diltiazem in patients with HFrEF, providing a mortality benefit. (ESC) 14
In HFrEF patients, the lowest effective dose of a beta‑blocker should be used for rate control, and amiodarone is an alternative when the patient is hemodynamically unstable or has severely reduced LVEF. (ESC) 14

Avoid diltiazem in any patient with systolic or decompensated heart failure, even if initially hemodynamically stable; beta‑blockers or digoxin are safer options. (ESC) 14
Do not administer diltiazem in pre‑excited atrial fibrillation (wide‑QRS with delta waves), as this can be fatal. (ACC) 15
Diltiazem alone is insufficient for multifocal atrial tachycardia (MAT) associated with severe pulmonary disease; treatment should focus on correcting hypoxemia and acidosis first. (ACC) 15

The 2015 ACC/AHA/HRS guidelines assign intravenous diltiazem a Class I, Level B recommendation as the preferred intravenous calcium‑channel blocker for rapid ventricular rate control in hemodynamically stable atrial flutter, citing its proven safety and efficacy. 16